Ads
related to: Acute Myeloid Leukemia- Side Effects & Safety
Learn About Possible Side Effects
You May Experience During Treatment
- Ph+ CML-CP Treatment
Visit The Patient Website To
Learn More About This Treatment.
- Understanding Ph+ CML-CP
Patients With The T315I Mutation,
Learn About A Treatment Option.
- Treatment Challenges
Patients, Learn About Setting
Goals & Reaching Milestones.
- Side Effects & Safety
Search results
HanxBio announces the publication of a research paper in Scientific Reports on preclinical...
FOX 4 Kansas City· 3 days agoHanxBio today announced that it has published a research article titled "Narazaciclib, a novel...
Why Big Pharma Is Following Novartis' Lead In A $25 Billion Market
Investor's Business Daily· 7 hours agoThat could be why the first generation of radiopharmaceuticals were flops, Seth, the Actinium CEO,...
Kura Oncology Gets Breakthrough Designation For Leukemia Therapy
Market Watch· 3 days agoThe San Diego-based biopharmaceutical company said the U.S. Food and Drug Administration had granted ziftomenib the status as a potential treatment for relapsed/refractory NPM1-mutant
FDA grants breakthrough status for Kura Oncology's AML drug candicate By Investing.com
Investing.com· 3 days agoFood and Drug Administration (FDA) has awarded Breakthrough Therapy Designation to its drug...
Deverra Therapeutics Granted FDA Fast Track Designation for DVX101
Digital Journal· 23 hours agoDesignation Validates Preliminary Data and Supports Accelerated Drug Development SEATTLE, WA / ACCESSWIRE / April 24, 2024 / Deverra Therapeutics, Inc., a clinical-stage biotechnology company ...
Bio-Path (BPTH) Rises on Upbeat Updates From Blood Cancer Study
Zacks via Yahoo Finance· 6 days agoBio-Path (BPTH) gains 30% on encouraging developmental updates from the early-stage study of its...
Small Business - The Roanoke-Chowan News-Herald | The Roanoke-Chowan News-Herald
Roanoke-Chowan News-Herald· 8 hours agoSAN DIEGO, April 25, 2024 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today announced that it will
CAR-T Plus Stem-Cell Transplant Promising for CD7+ Blood Cancers
MedPage Today· 2 days agoA strategy of sequential CD7 chimeric antigen receptor (CAR) T-cell therapy and haploidentical...
Promising Treatment Approach for Aggressive Leukemia Identified
Technology Networks· 7 days agoScientists have uncovered a promising treatment strategy for an aggressive type of leukaemia –...
Kura Oncology Receives Breakthrough Therapy Designation for Ziftomenib in NPM1-Mutant AML
Morningstar· 3 days agoFood and Drug Administration (FDA) for the treatment of patients with relapsed/refractory (R/R) NPM1-mutant acute myeloid leukemia (AML ...
Ads
related to: Acute Myeloid Leukemia